SCHEMBL9288154

SCHEMBL9288154

O=C1Nc2ccccc2C(c2ccc(Cl)cc2)=NC12CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 5/20 0.45
GABRA1 P14867 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
CNR1 P21554 1/20 0.41
NTSR1 P30989 1/20 0.41
OPRK1 P41145 1/20 0.41
PDE4D Q08499 1/20 0.41
NEK2 P51955 1/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
ALB P02768 1/20 0.40
KMT2A Q03164 1/20 0.40
GALR3 O60755 1/20 0.40
IDO1 P14902 1/20 0.40
CCKAR P32238 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28914571 0.88 GABRA1 (0.55) CCKBRGABRA1GABRG2GABRB3GABRA5
SCHEMBL19585553 0.82 GABRA1 (0.44) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL10510434 0.81 GABRA1 (0.50) CCKBRGABRA1GABRG2GABRB3GABRA5
SCHEMBL10508461 0.79 CNR1 (0.46) CCKBRGABRA1GABRG2GABRB3GABRA5
SCHEMBL10511185 0.79 OPRD1 (0.40) CCKBRGABRA1GABRG2GABRB3GABRA5
SCHEMBL10507348 0.79 DRD2 (0.48) CCKBRCNR1NTSR1OPRK1PDE4D
SCHEMBL10510649 0.77 CHRNA7 (0.46) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10509580 0.77 CNR1 (0.56) CCKBRGABRA1GABRG2GABRB3GABRA5
Hydrochloric Acid SCHEMBL10510329 0.77 CNR1 (0.44) CCKBRGABRA1GABRG2GABRB3GABRA5
SCHEMBL10508564 0.76 GABRP (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249161-B2 Bromodomain inhibitors and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-02-02 US disclosed
US-9249161-B2 Bromodomain inhibitors and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-02-02 US disclosed
US-20140005169-A1 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2014-01-02 US disclosed
WO-2012075456-A1 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2012-06-07 WO disclosed
WO-2012075456-A1 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005169-A1 BROMODOMAIN INHIBITORS AND USES THEREOF BRD4, BRPF3, BRDT CCKBR 3531/4885GABRA1 1807/4885GABRG2 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.